#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malignant glioma Myeloproliferative neoplasm Cutaneous T-cell lymphoma stage I Idiopathic inflammatory myopathy Microscopic polyangiitis Partial lipodystrophy Cerebral haemorrhage Neuromyelitis optica spectrum disorder Brain injury Testicular leiomyosarcoma Acute graft versus host disease in liver Myotonic dystrophy Familial amyotrophic lateral sclerosis Chronic inflammatory demyelinating polyradiculoneuropathy B precursor type acute leukaemia More trials…

    Learn about Rare Diseases

    Behcet’s syndrome – Basic Information Mantle cell lymphoma refractory – Treatment Hereditary hypophosphataemic rickets – Life with Disease Cerebral arteriovenous malformation haemorrhagic Pleural mesothelioma malignant – Basic Information IgA nephropathy – Life with Disease Ehlers-Danlos syndrome – Basic Information Pituitary-dependent Cushing’s syndrome – Life with Disease Propionic acidaemia – Trials in Disease Nephroblastoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ciltacabtagene Autoleucel Gabapentin SODIUM TETRACHLOROPALLADATE Carbidopa Nirogacestat Hydrobromide Naloxone Hydrochloride Bi 690517 Formoterol Fumarate SRSD107 Trastuzumab Zinc Acetate Dihydrate Simeticone Omp72 AVTX-009 Rimegepant Cloxacillin Sodium Istem-01 Bms-986408 Tilmanocept Mometasone Furoate More therapies…

    Learn about Your Condition

    Oedema Senile dementia Hypervolaemia Renal transplant Myocardial ischaemia Adenocarcinoma gastric Hernia repair Diffuse large B-cell lymphoma Coma Orthostatic hypotension Gouty arthritis Ischaemic stroke Embolism venous Diabetic foot infection Alagille syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hopital Prive Jean Mermoz

Hopital Prive Jean Mermoz

5t Agnqye Jufj Myzcxyx Luqgs 6emnse Fvypsb

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • Evaluating the use of capecitabine, oxaliplatin, fluorouracil, folinic acid, and irinotecan to personalize chemotherapy for patients with stage III colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer stage III
    Investigated Drugs:
    • Capecitabine
    • Fluorouracil
    • Folinic Acid
    France Sweden

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    • Topotecan Hydrochloride
    • Doxorubicin Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2

  • Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Sotorasib
    • Bevacizumab
    • Calcium Folinate
    Austria Belgium Bulgaria Czechia Denmark Estonia +12

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Exemestane
    • Goserelin
    France Germany Italy The Netherlands Spain

  • A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Azd8205
    • Doxorubicin
    • Paclitaxel
    Austria Belgium Czechia Denmark Finland France +9

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Capivasertib
    • RLY-2608
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Denmark France +10

  • A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • FRUQUINTINIB
    • Tipiracil Hydrochloride
    • Trifluridine
    France Germany Spain

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France

  • Study of bevacizumab and trifluridine combination given bi-weekly to reduce severe neutropenia in patients with metastatic colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal adenocarcinoma
    Investigated Drugs:
    • Bevacizumab
    • Trifluridine
    France
1 2 3 … 10
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!